media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Have You Booked Your Meetings Yet?

A practical 4-week guide to identifying the right contacts, sending meeting invitations, preparing for discussions, and following up after the show. CPHI Milan 2026 will take place from 6–8 October at Fiera Milano, Italy. With less than a month to go, flights, booth materials and product brochures may already be on your checklist. But there is another task worth starting now: Booking meetings with the people you actually want to meet. Trade shows are great for unexpected connections. But if you already have prospects who requested a quote, discussed a sample, showed interest in your products, or simply have a strong business fit, it makes sense to contact them before the exhibition. A simple “Welcome to visit our booth” may not be enough. Give people a reason to meet you, tell them what you would like to discuss, and make it easy to choose a time. 1. Start with what ...
- Source: drugdu
- 32
- September 10, 2026
Health Asia

Organiser：Ecommerce Gateway Pakistan (Pvt.) Ltd Time：September 10th – 12th, 2026 Address：University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Supplies‌: Medical diagnostic equipment & supplies, pharmaceuticals, electronic medical devices & instruments, ambulance equipment, medical reagent equipment, disposable medical devices ‌Hospital Supplies‌: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical medical instruments, medical uniforms & bedding, hospital furniture, first-aid equipment, maternal and infant care equipment, disinfection equipment, orthopedic prosthetics, air filtration devices, medical blood pressure diagnostic instruments, heart rate monitors, ultrasound equipment, X-ray medical diagnostic equipment, dialysis machines, physiotherapy equipment ‌Laboratory Equipment‌: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, quality inspection equipment, laboratory renovation and upgrading technologies, consumables and related software ‌Pharmaceuticals & Healthcare‌: Medical ophthalmic pharmaceuticals, orthopedic pharmaceuticals, traditional Chinese patent medicines, Western medicines, traditional Chinese healthcare medicines, nutritional foods, pharmaceutical chemical intermediates ‌Healthy ...
- Source: drugdu
- 30
- September 10, 2026
Fosun Pharma’s FXS5626 Tablets Approved for Phase II/III Trial, TYK2/JAK1 Dual-Target Inhibitor for Vitiligo | Clinical Progress

On September 8, Fosun Pharma (600196.SH; 02196.HK) announced that its controlling subsidiary Fosun Pharma Industrial has received approval from China’s National Medical Products Administration (NMPA) to conduct a Phase II/III adaptive seamless design clinical trial of FXS5626 tablets for the treatment of non-segmental vitiligo. FXS5626 is an oral small molecule JAK inhibitor (TYK2/JAK1 dual-target inhibitor) licensed in by the Group, which holds exclusive rights for research, development, production, registration, and commercialization of the drug in mainland China, Hong Kong, and Macau. FXS5626 (original project code AC-201) is an oral small molecule TYK2/JAK1 dual-target inhibitor, primarily intended for the autoimmune disease field. Vitiligo is a common acquired pigmentary depigmentation skin disorder, with non-segmental vitiligo being the most common type, and its pathogenesis is closely related to autoimmune mechanisms. Currently, treatment options for vitiligo are limited. By inhibiting the JAK-STAT signaling pathway, JAK inhibitors can regulate immune responses and promote melanocyte function ...
- Source: drugdu
- 40
- September 9, 2026
InnoCare’s First Bispecific ADC ICP-B381 Approved for Clinical Trials, Targeting PSMA/STEAP1 for Prostate Cancer | Clinical Progress

On September 9, InnoCare (688428.SH; 09969.HK) announced that its self-developed bispecific ADC drug ICP-B381, targeting PSMA and STEAP1, has been approved by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of solid tumors including prostate cancer. This is the company’s first bispecific ADC approved for clinical trials and its third ADC innovative drug to enter the clinical stage. ICP-B381 is the first bispecific ADC developed by InnoCare based on its proprietary ADC platform, consisting of a humanized anti-PSMA/STEAP1 antibody, the company’s self-developed next-generation irreversible linker, and a potent payload. PSMA (prostate-specific membrane antigen) and STEAP1 (six-transmembrane epithelial antigen of prostate 1) are both highly expressed on the surface of prostate cancer cells. By simultaneously targeting these two antigens, ICP-B381 can effectively cover heterogeneous tumor cells, reduce tumor escape risk, and potentially benefit more patients. Preclinical studies have shown ...
- Source: drugdu
- 41
- September 9, 2026
another blockbuster imported drug approved for marketing in China

On September 3, 2026, according to the official website of the National Medical Products Administration (NMPA) of China, Tasultinib Succinate Tablets, submitted by SciSheng Pharmaceuticals (China) Co., Ltd., were approved for marketing. Public information shows that it was included in the priority review process on November 27, 2025, with the indication of treating unresectable biliary tract cancer patients who have failed prior chemotherapy and have been confirmed to have the FGFR2 fusion/rearrangement gene. China has one of the highest age-standardized incidence rates of biliary tract tumors (BTC). Intrahepatic cholangiocarcinoma (ICC) is a subtype of BTC that originates in the intrahepatic bile ducts and may affect approximately 60,000 people in China each year. Cholangiocarcinoma accounts for about 10%-15% of all primary liver malignancies, making it the second most common primary liver cancer after hepatocellular carcinoma. Tasurgratinib, developed by Eisai, is an oral selective tyrosine kinase inhibitor of fibroblast growth factor receptor ...
- Source: drugdu
- 37
- September 9, 2026
A New Battlefield for China’s Innovative Drugs

Recently, Reindeer Biotech announced that the Australian Therapeutic Goods Administration (TGA) has formally accepted its application for marketing authorization of its CAR-T cell product, Ikiorenzai Injection (FUCASO), for inclusion in the Australian Therapeutic Goods Register (ARTG) and entered the evaluation stage for the treatment of adult patients with relapsed/refractory multiple myeloma (r/r MM) who have progressed after at least three lines of prior therapy. This event is not only a milestone in the internationalization of a single company, but also reflects a profound shift in the strategic positioning of Chinese innovative drugs in Australia. For a long time, Australia has been a “hotbed” and “stepping stone” for Chinese pharmaceutical companies to conduct early clinical trials, but there are very few cases of commercialization and listing in Australia. As clinical benefits gradually reach their peak and market competition intensifies, Chinese pharmaceutical companies, represented by Reindeer Biotech, are attempting to bridge the ...
- Source: drugdu
- 36
- September 9, 2026
New lung cancer drug launched

Recently, Betta Pharmaceuticals’ ensartinib hydrochloride capsules were approved by the National Medical Products Administration for adjuvant therapy after surgery in patients with anaplastic lymphoma kinase (ALK)-positive stage IB to IIIB non-small cell lung cancer (NSCLC) . According to the approved indication, patients must have previously undergone surgical resection, and their choice to receive adjuvant chemotherapy can be determined by their physician. the third indication approved for ensartinib , making it the first domestically produced ALK inhibitor to be approved for this indication. Previously, the only drug approved for this indication globally was Roche’s alectinib. The approval of this indication targets a long-standing unmet clinical need. Lung cancer is a malignant tumor with high incidence and mortality rates globally and in China . According to the “Analysis of the Epidemiology of Malignant Tumors in China in 2022” released by the National Cancer Center, there were 1.06 million new cases of lung ...
- Source: drugdu
- 40
- September 9, 2026
【EXPERT Q&A】If the buyer only says “Send me your catalog”, should the entire catalog be sent directly?

Drugdu.com expert’s response: When engaging in pharmaceutical foreign trade, you often receive very short inquiries that simply say: “Send me your catalog.” Some buyers only leave their country and email address, with no mention of specific products, purchase quantities, or whether they are importers, distributors or end users. Many suppliers’ first reaction is to send over the company catalog directly. It is a dozens-of-page PDF covering a full product line, complete with images, parameters and company introduction. After sending it, they just wait for the buyer’s reply. But more often than not, there is no follow-up response. It is not that the catalog is completely useless. The problem is that when you send the entire catalog directly, the buyer may not bother to read it carefully. Especially for products like APIs, excipients, medical devices and consumables, buyers rarely go through a catalog “just browsing casually”. They probably already have a ...
- Source: drugdu
- 37
- September 9, 2026
New At-Home Option for Alzheimer’s! Lecanemab Subcutaneous Auto-Injector Pen Approved in China | Approval Alert

Recently, China’s National Medical Products Administration (NMPA) approved the marketing of the anti-amyloid beta antibody drug lecanemab subcutaneous auto-injector pen for the treatment of early Alzheimer’s disease. This is the first and currently only anti-amyloid therapy in China that can be administered at home, making China the second country globally to approve this subcutaneous formulation. The at-home injection product is expected to be officially launched by the end of 2026 or early 2027. Lecanemab, jointly developed by Eisai and Biogen, is an anti-amyloid beta protofibril antibody that slows the progression of Alzheimer’s disease by clearing beta-amyloid deposits in the brain. Previously, the intravenous infusion formulation of lecanemab was already approved in China, requiring patients to regularly visit hospitals for infusion treatment. The newly approved subcutaneous auto-injector pen allows patients to self-inject at home, significantly improving medication convenience and patient adherence. Patients now have two administration route options: they can choose ...
- Source: drugdu
- 50
- September 8, 2026
Sinopharm Group and Hansoh Pharmaceutical Reach Strategic Cooperation, Launch Four Special Projects Including Broad Market, Medical Access, Retail, and DTP | Market News

On September 8, according to Sinopharm Group (01099.HK), Sinopharm Group and Hansoh Pharmaceutical (03692.HK) recently reached a strategic cooperation. Based on years of in-depth cooperation, and centered on the goals of deepening industry-commerce collaboration and empowering high-quality industrial development, the two parties signed a strategic cooperation agreement and simultaneously launched four special cooperation agreements covering broad market, medical access, retail, and DTP, promoting the upgrade of industry-commerce cooperation from traditional business docking to a full-chain, full-cycle strategic collaboration. This strategic cooperation covers four key directions: in the broad market, the two parties will jointly promote the penetration of Hansoh Pharmaceutical’s products to grassroots medical markets to improve drug accessibility; in medical access, they will collaborate to advance product access and clinical application in hospitals at all levels; in retail, they will strengthen cooperation in retail pharmacy channels to expand the out-of-hospital market; in DTP (Direct to Patient), they will establish ...
- Source: drugdu
- 48
- September 8, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.